PHP42 Health Economics in the Czech Republic and Insurance Coverage Decision Making in 2008-2009: A Retrospective Analysis  by Fuksa, L. et al.
market share across Europe. G-CSFs have achieved the highest market penetration
levels by value and GH the lowest across Europe. We identify four main drivers of
market penetration differences. Price has the highest impact along with the re-
sponse rate to the therapy. The efficacy of biosimilars in clinical trials as well as the
economic mind-set of prescribers (office-based vs. hospital-based) also drive bio-
similar market uptake. CONCLUSIONS: The study concludes with policy implica-
tions to regulate the uptake of biosimilars given different market conditions.
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OBJECTIVES: The recent AMNOG health care reforms in Germany provide a unique
view of a changing pricing system in Europe. With other European markets such as
the UK planning similar reforms, we aimed to review the impact of AMNOG on drug
pricing in Germany and distil lessons for other markets facing similar reforms.
METHODS: Secondary research was conducted to review IQWiG’s benefit assess-
ment activity since the AMNOG reforms. The outcomes of these benefit assess-
ments were assessed alongside rationale for decisions and pricing outcomes.
RESULTS: At the time of writing, 24 products have been subject to benefit assess-
ments by IQWiG. Of these, 12 were considered to show some level of added benefit
relative to the comparator, with the remainder showing no benefit. Selection of
inappropriate comparators was commonly cited by IQWiG as a reason that no
additional benefit was demonstrated. Under AMNOG, products displaying no
added benefit will be subject to automatic reference pricing, subjecting these prod-
ucts to generic pricing levels. As a result, there have been a number of high profile
instances of manufacturers withdrawing products from the German market as a
result of negative benefit assessment – most notably GSK with Trobalt and Pfizer
with Xiapex. In instances where additional benefit is shown, Brilique is currently
the only product has progressed through price negotiations with the GKV, resulting
in a modest price premium. CONCLUSIONS: The AMNOG reforms provide an ex-
cellent live example of a national level shift towards a “value based” pricing sys-
tem. The benefit assessments and consequent price levels may provide an indica-
tor of pricing that may be achieved following the implementation of value based
pricing in the UK. However, policy makers in the UK should be conscious of the
potential negative implications of these reforms in the way of product withdraw-
als.
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OBJECTIVES: A number of jurisdictions have adopted special funding arrange-
ments to provide extra payments to hospitals using certain technological innova-
tions to encourage use where existing financing may be absent or insufficient. The
objective of this research was to explore the use of these arrangements for medical
technologies in the English NHS. METHODS: A structured on-line survey instru-
ment was developed to gain insights into the use of special payments. An invitation
to participate with a link to the on-line survey was disseminated to NHS hospital
Finance Managers. A total of 25 surveys were returned and analysed. RESULTS:The
majority (75%) of responding hospitals have sought support from Commissioners
to approve special payments. In 35% of cases, the payment was for medical devices,
followed by drugs (31%), diagnostics (19%), and other technologies (15%). Respon-
dents highlighted specific technologies where special payments have been nego-
tiated, including Transcatheter Heart Valves, Neuromodulation Implants, and Gas-
tric Bands, among others. In most cases, such arrangements were requested
because the technology was either excluded from the PbR system or the existing
HRG tariff was not sufficient to cover costs. In half of the examples, the technology
was fully or partially paid for. However, it was not uncommon for Commissioners
to request additional evidence before making a decision or reject special payment
applications altogether. A range of evidence (therapeutic benefit, reduced hospital
admissions/length of stay, costs/cost-effectiveness) is considered to determine
payment amounts. Once negotiated, payment arrangements are typically put in
place for 1-3 years. Overall, NHS managers had mixed perceptions of the effective-
ness of special payments and identified several challenges, such as a disinterest
and insufficient expertise amongst Commissioners to consider submitted evidence
and the length of time to agree payments. CONCLUSIONS:While special payments
provide some flexibility for encouraging the adoption of technological innovation,
a number of improvements are needed to effectively meet this aim.
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OBJECTIVES: Since 2008 the Czech legislation requires health economic analysis
(HEA) to be a part of all new drug reimbursement applications submitted to State
Institute for Drug Control (SUKL): without any specific guidelines, however. In order
to see the real-world impact of the legislation change, we investigated past (2008/
2009) innovative molecules’ dossiers in terms of quality of their HEAs according to
newly (2012) developed methodology of SUKL and also their impact on the respec-
tive decisions on coverage. METHODS: We selected all (22) applications for inno-
vative drugs limited to specialized centers. We then briefly described the HEAs in
terms of their perspective and type of analysis. The HEAs were further confronted
with a ‘HEA checklist’ based on the new SUKL methodology to identify common
drawbacks and faulty issues in past HEAs. Consequently the respective coverage
decisions were investigated. RESULTS: Of the innovative molecules’ 22 dossiers
investigated, only in 13 (59%) HEA was present. Two (15%) were cost-minimization
studies, the rest were cost-effectiveness analyses, of which three (23%) were cost-
utility. There was no apparent standardization in the analyses along with an obvi-
ous lack of transparency. Indeed, ‘proper description of input data and their
sources’ was the point in the HEA checklist to be most often marked as ‘unsatis-
factory’. Review of the consequent SUKL’s coverage decisions revealed that, irre-
spective of the HEA quality and even presence, all 22 (100%) applications were given
a positive coverage decision. CONCLUSIONS: The present pilot study showed that
in the first two years since introducing the obligation of health economic analyses
be part of coverage applications, the system was largely ineffective. This finding
stresses the necessity of introduction of a standardized methodology into the as-
sessment and appraisal processes. Moreover, our study identified the key problem-
atic areas to be specifically addressed by both the authors and assessors of future
analyses.
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OBJECTIVES: In an effort to remedy a highly fragmented system of health care
financing, Russia has introduced a series of reforms targeted streamlining public
and private funding. We aimed to understand how the recent reforms have im-
pacted pricing and reimbursement and how this is expected to change in the
future.METHODS:We conducted in-depth secondary research through an analysis
of Russian health care policies including the new DLO reimbursement programme
and the Essential and Most Important Medicines List (EML). Research was also
conducted on the roles of private insurance companies and private out-of-pocket
expenses. Expectation of how these reforms will shape pricing and reimbursement
in the future was assessed through a qualitative survey of key payers. RESULTS:
Increases in the percentage of GPD spent on health care and the procurement of
additional funding have led to a boom in the size of the Russian pharmaceutical
market. However, although medicines on the EML are fully reimbursed, coverage
does not include drugs for most outpatients, resulting in significant out-of-pocket
spending. Private insurers have also failed to produce competition due to lack of
incentives and legislation has caused rises in drug pricing. Payers expect that eco-
nomic growth and increased government spending on health care will continue to
increase the commercial attractiveness of the Russian pharmaceutical market.
However, several competing factors may cause legislative barriers to entry and
create a more challenging pricing and reimbursement environment. These con-
cerns arise from a newly imposed price cap on EML medicines, the exclusion of
certain drugs from the EML, legislation encouraging domestic growth, and a lack of
transparency regarding reimbursement decisions. CONCLUSIONS: New drug pric-
ing regulations and funding will likely create advantages for domestic pharmaceu-
tical companies while potentially decreasing foreign presence by creating a
tougher pricing and reimbursement environment.
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OBJECTIVES: Accessibility (time to financing decision) to new medicines is a major
concern in Europe. Recently the European Commission has proposed to streamline
and reduce the duration of national decisions on pricing and reimbursement of
new medicines. The objective of this study was to evaluate the accessibility to
medicinal products with new molecules or new therapeutic indications (NMNTI) in
Portugal, since 2007 and characterize the determinants of the assessment process
by the Portuguese Ministry of Health. METHODS: Data on 119 NMNTI reimburse-
ment applications to the PMH between January 2007 and June 2011 was kindly
provided by submitting pharmaceutical companies. Time to financing decision
was assessed using the Turnbull non-parametric estimator and variability in time
to financing decision was explored using accelerated failure time regression mod-
els with Gaussian mixture distributions, both allowing for interval, left and right
censoring. The likelihood of public financing and its determinants was evaluated
through the estimation of logistic regression models. RESULTS: Median time from
submission to decision 331 days (95%CI: 292-398) was excessive relative to those in
the Law for the decision: 70 days (hospital) and 110 days (ambulatory). In hospital
medicines no decision was taken in less than 70 days. Only 10% of the decisions
from ambulatory drugs were taken within the timelines in the law. Of particular
concern was median decision times for orphan medicines (718 days), oncology
drugs (743 days) and new therapeutic indications of medicines already reimbursed
(890 days). From a vast number of variables studied, only in cardiovascular medi-
cines the likelihood of non-public financing was significant lower (p0.026).
CONCLUSIONS:Accessibility to new medicines or medicines with new therapeutic
indications in Portugal is compromised by an excessively long assessment process
by the Portuguese Ministry of Health. Of particular concern is accessibility to or-
phan and oncology drugs.
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